Oncology Reimbursement Changes Could Close Small Practices, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen remains confident its oncology portfolio is on track to deliver growth despite changes in reimbursement in the market, Associate Director-Investor Relations Laura Biswas said